scholarly journals The Waiting Time of Prostate Cancer Patients in Poland

2019 ◽  
Vol 16 (3) ◽  
pp. 342 ◽  
Author(s):  
Karolina Osowiecka ◽  
Sergiusz Nawrocki ◽  
Marcin Kurowicki ◽  
Monika Rucinska
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Cancer Patients ◽  
Median Time ◽  
Waiting Time ◽  
Common Reason ◽  
Histopathological Diagnosis ◽  
Place Of Residence ◽  
Oncology Centre ◽  
The Impact

Background: Prostate cancer is the second most common reason of mortality due to cancer among men in Poland. The study aimed to determine the waiting time for diagnosis and treatment of prostate cancer. Methods: The study was carried out on patients treated for prostate cancer from May 2014 to February 2015 at five oncological centres in Poland. The median waiting time was measured from the time cancer was suspected to the histopathological diagnosis (SDI), from the cancer suspicion to the start of treatment (STI) and from the diagnosis to the start of treatment (DTI). Results: 123 males treated for prostate cancer were included for analysis. The median time for SDI, STI and DTI was 7.7, 18.7 and 8.7 weeks, respectively. Place of residence was the only factor which influenced STI (p = 0.003). For patients, who started treatment with radiation therapy DTI was longer than for other patients (p < 0.001). Conclusions: Median times of STI, SDI and DTI for prostate cancer patients in Poland are similar to the intervals described in other countries. Patients, who lived further from an oncology centre waited longer for treatment. The impact of waiting time in the case of prostate cancer on improving the prognosis is still unclear.

The effect of naturopathic and nutritional supplement treatment on tumor response, control, and survival in prostate cancer patients treated with radiation therapy

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e16088-e16088
Author(s):  
T. C. Birdsall ◽  
L. Cain ◽  
J. Martin ◽  
S. M. Birdsall ◽  
L. Wiersum ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
High Risk ◽  
Clinical Response ◽  
Cancer Patients ◽  
Median Time ◽  
Tumor Response ◽  
Definitive Treatment ◽  
Tumor Stages ◽  
Psa Nadir

e16088 Background: Potential antagonism of clinical response to cancer treatment by naturopathic/nutritional supplements (NNS) with anti-oxidant activity has been suggested. This study assessed effects of NNS on tumor response to radiation therapy (RT) in prostate cancer patients (PCpts). Methods: Of 134 RT-treated PCpts with localized tumors, 69 received NNS (+NNS; median age=62.0 yrs) and 65 did not (-NNS; median age=61.5 yrs). Based on pre-RT PSA, 52low (4–10 ng); 13 intermediate (10–20 ng); and 4 high risk (> 20 ng) PCpts were +NNS and 50, 10, and 5 low, intermediate & high risk PCpts were -NNS. Tumor stages for +NNS were T1c (39%); T2a (44%); T2b (10%); T2c (5%) with 1 T3b tumor and were T1b (3%); T1c (46%); T2a (32%); T2b (12%); and, T2c (5%) with 1 T3a tumor for -NNS cohorts. RT consisted of external beam therapy (4500–5000 cGy) + HDR brachytherapy (600–650 cGy/fraction x 2–3 fractions) administered over 6–8 weeks. NNS regimens (range 1–7 antioxidants) included Green Tea Extract, Melatonin, high-potency multivitamins, vitamin C, and vitamin E. All pts were monitored ≥ 24 months post RT. Hormonal therapy (HT; oral bicalutamide (50 mg/day) ±leuprolide depot (22.5 mg IM q 3 months) as neoadjuvant or adjuvant HT was given to 39 (57%) and 38 (58%) PCpts in the +NNS and -NNS cohorts respectively. Results: For the +NNS cohort that did not receive HT, PSA levels were 5.05; 0.285; and 0.356 ng at pretreatment, nadir and ≥ 24 months followup respectively with PSA nadir at 27 months and median followup of 36 months. The corresponding values for the -NNS cohort were 5.6, 0.54, and 0.585 ng with PSA nadir at 25 months and median followup of 29.6 months. Differences were not statistically significant. For the +NNS cohort that did receive HT, PSA levels were 6.8, 0.03 and 0.12 ng at pretreatment, nadir and ≥ 24 months followup with median time to nadir = 4.3 months and median followup = 29.2 months. Corresponding values for -NNS cohort were 6.9, 0.03, and 0.11 with median time to nadir = 3.6 months and median followup = 30.5 months. Differences were also not statistically significant. Conclusions: This study shows that NNS with antioxidant activity do not interfere with clinical response to RT ± HT as definitive treatment for limited stage prostate cancer. No significant financial relationships to disclose.

The impact of time to metastasis on survival in treatment-naïve prostate cancer patients.

2015 ◽  
Vol 33 (7_suppl) ◽  
pp. 212-212
Author(s):  
Shusuke Akamatsu ◽  
Kenny Lynch ◽  
Peter Black ◽  
Martin Gleave ◽  
Larry Goldenberg ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Median Time ◽  
De Novo ◽  
Patient Characteristics ◽  
Initial Diagnosis ◽  
Significant Difference ◽  
Treatment Naïve ◽  
The Impact

212 Background: With the emergence of novel therapies, the treatment of advanced prostate cancer has evolved. However, patients eventually succumb to their metastatic disease. Nonetheless, little is known about the impact of time to metastasis on survival. To further expand on this, we separated metastatic prostate cancer patients into three groups according to the timing of metastasis and analyzed their survival. Methods: From 2008 to 2013, 157 CRPC patients were identified in our database. Of those, 92 with metastasis and sufficient data were analysed. The patients were classified into three groups according to the timing of metastasis. There were 35 de novo –M (metastasis within three months of initial diagnosis), 26 CSPC-M (initially metastasis free, metastasis found more than 6 months prior to CRPC), and 31 CRPC-M (metastasis found within 6 months of becoming CRPC, or after becoming CRPC). Patient characteristics were analyzed, and survival was calculated. Results: Median follow up were 2.2, 9.6, and 11.8 years for de novo-M, CSPC-M, and CRPC-M. 85 and 84 % in the CSPC-M and CRPC-M respectively had local therapies by surgery and/or radiation. The types of local therapies were similar between the groups. Mean time to PSA recurrence after intial therapy were 3.5 and 2.2 years for CSPC-M and CRPC-M, and median time to metastasis were 4.4 and 11.4 years respectively. Treatments after CRPC included Abiraterone, Enzalutamide, and Docetaxel, and the use of these agents were similar between the groups. Median time to CRPC were 1.4, 6.2, and 8.6 years, and median overall survival after diagnosis were 3.7, 12.3, and 15.8 years for de novo-M, CSPC-M, and CRPC-M. Conclusions: The overall survival and time to CRPC were significantly shorter in de novo-M. Although there was a marked difference in time to metastasis between CSPC-M and CRPC-M, there was no statistically significant difference in overall survival. Either treated with hormone therapy before or after emergence of metastasis, survival of more than 10 years after initial diagnosis is possible.

Sign in / Sign up

Export Citation Format

Share Document